Biomoda Inc. (BMOD.OB) Announces Completed Sample Collection and Patient Enrollment Pilot Study
Biomoda, Inc., a specialized cancer diagnostics company, recently announced the completion of its patient enrollment and sample collection in a pilot study for the clinical sensitivity of its CyPath® label solution for the early detection of lung cancer. The data and results from the study will be released when they become available. Biomoda is looking forward to an FDA approval of its screening technology as a Class III medical device. Biomoda’s President John Cousins is also pursuing a CE Mark to make CyPath® commercial in Europe. CyPath® is currently available for only for investigational use only. “This is a significant…